Circadian changes direction

By Dylan Bushell-Embling
Thursday, 12 June, 2008

Australian biotechnology firm Circadian Technologies (ASX: CIR) is restructuring and plans to evolve from a biotech incubator to a drug development company which will specialise in cancer treatments.

Circadian has appointed a product development review group, which includes both the former head of development and the former project team leader from US biotech Amgen.

The group will oversee the company's commercialisation of cancer treatment drugs based on its VEGF inhibitors, developed by subsidiary Vegenics.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd